Search
for
Sort by
Research 511–540 of 1000+
- Principles of Hair Cycle Control
- 9 Role of 5α-reductase in health and disease
- Congenital Adrenal Hyperplasia
- Androgen excess is the key element in polycystic ovary syndrome
- Diagnosis of Polycystic Ovary Syndrome
- Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome
- Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus
- Polycystic Ovary Syndrome: Update on Diagnosis and Treatment
- Hair loss in women with hyperandrogenism: Four cases responding to finasteride
- LASER-ASSISTED HAIR REMOVAL
- Global Adiposity and Thickness of Intraperitoneal and Mesenteric Adipose Tissue Depots Are Increased in Women With Polycystic Ovary Syndrome (PCOS)
- Polycystic Ovarian Syndrome
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders
- Hormonal contraceptives: pharmacology tailored to women's health
- Polycystic Ovary Syndrome
- Dermatologic manifestations of endocrine disorders
- <i>Polycystic Ovary Syndrome in Adolescence</i>
- Drug Reactions Affecting Hair: Diagnosis
- Diagnosis of hyperandrogenism: clinical criteria
- Prevalence of polycystic ovaries in women with androgenic alopecia
- Androgen excess: Investigations and management
- Intracrinology and The Skin
- Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome
- Safety of testosterone treatment in postmenopausal women
- Side-Effects of Spironolactone Therapy in the Hirsute Woman
- Inhibition of skin 5α-reductase by oral contraceptive progestins<i>in vitro</i>
- Spironolactone is an Effective and Well Tolerated Systemic Antiandrogen Therapy for Hirsute Women*
- Diagnosis of hyperandrogenism: Biochemical criteria
- Androgenetic alopecia in men and women
- Dermatologic Manifestations of Polycystic Ovary Syndrome